camptothecin has been researched along with Leukemia in 58 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 32 (55.17) | 18.2507 |
2000's | 22 (37.93) | 29.6817 |
2010's | 4 (6.90) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Asao, Y; Matsuda, H; Miyagawa, K; Nemoto, Y; Yoshida, K; Yoshikawa, M | 1 |
Bailly, C; Baldeyrou, B; Beauchard, A; Besson, T; Chérouvrier, JR; Domon, L; Jaunet, A; Lansiaux, A; Murillo, L; Picot, L; Thiéry, V | 1 |
Addo, SN; Das, SG; Doshi, JM; Hermanson, DL; Srinivasan, B; Tian, D; Xing, C | 1 |
Dezhenkova, LG; Kalinina, AA; Kaluzhny, DN; Kubbutat, M; Luzikov, YN; Pommier, Y; Preobrazhenskaya, MN; Romanenko, VI; Schols, D; Shchekotikhin, AE; Shtil, AA; Tatarskiy, VV; Treshalin, MI; Treshalina, HM; Tsvetkov, VB; Volodina, YL | 1 |
Huang, HL; Huang, RL; Huang, YL; Lin, TW | 1 |
Chen, GQ; Duan, XF; Wen, DH; Zhao, M | 1 |
Chen, GQ; Huang, Y; Wang, LS; Yu, Y; Yuan, TT; Zhou, CX; Zhuang, HY | 1 |
Bligh, SW; Hartley, JA; Hartley, JM; Pan, X; Wang, Z; White, KN | 1 |
Wiart, C | 1 |
Chauvier, D; Kegelaer, G; Manfait, M; Morjani, H | 1 |
Bergamaschi, A; Darzynkiewicz, Z; De Nicola, M; Ghibelli, L; Grabarek, J; Smolewski, P; Teodori, L | 1 |
Bailly, C | 1 |
Kwee, JK; Maia, RC; Marques-Santos, LF; Silva, KL; Vasconcelos, FC | 1 |
Banai, Y; Gokulan, K; Khare, S; Linthicum, DS; Modiano, JF; Smith, R | 1 |
Austin, RC; Baumeister, P; Kaufman, RJ; Lee, AS; Mao, C; Reddy, RK | 1 |
Beauchemin, M; Bergeron, S; Bertrand, R | 1 |
Chen, GQ; Chen, Z; Du, KM; Gao, SM; Song, MG; Wang, Q; Xu, M; Yu, Y; Zhou, YH; Zhu, YS | 1 |
Hannemann, RE; Ramkrishna, D; Rundell, A; Sherer, E | 1 |
Akutsu, M; Furukawa, Y; Izumi, T; Kano, Y; Kobayashi, H; Mano, H; Tsunoda, S | 1 |
Barge, RM; de Vries, JF; Falkenburg, JH; Heemskerk, MH; Jedema, I; Nijmeijer, BA; van Dreunen, L; Wammes, LJ; Willemze, R | 1 |
Meropol, NJ | 1 |
Berg, SL; Blaney, SM; D'Argenio, DZ; Jacob, E; Scorsone, K | 1 |
Adams, DJ; Giles, F; Jacobsen, TF; Myhren, F; Rizzieri, DA; Sandvold, ML | 1 |
Donehower, RC; Grochow, LB; Kaufmann, SH; Rowinsky, EK; Slichenmyer, WJ | 1 |
Dubrez, L; Genne, P; Goldwasser, F; Pommier, Y; Solary, E | 1 |
DeJesus, A; Early, J; Giovanella, B; Kozielski, A; Mendoza, J; Pantazis, P; Vardeman, D | 1 |
Fujimori, A; Harker, WG; Hoki, Y; Kohlhagen, G; Pommier, Y | 1 |
DeJesus, A; Giovanella, BC; Kufe, D; Mendoza, JT; Pantazis, P; Rubin, E | 1 |
Adjei, A; Burke, PJ; Cheng, YC; Donehower, RC; Gore, SD; Grochow, LB; Jones, RJ; Kaufmann, SH; Rowinsky, EK | 1 |
Ariyoshi, Y; Ogawa, M | 1 |
Ellis, AL; Nowak, B; Plunkett, W; Zwelling, LA | 1 |
Darzynkiewicz, Z; Gong, J; Traganos, F | 1 |
Beran, M; Cazenave, L; Ellis, A; Kantarjian, HM; Keating, MJ; Koller, C; O'Brien, S; Plunkett, W; Rios, MB; Zwelling, L | 1 |
Ahmed, T; Bigman, K; Darzynkiewicz, Z; Gong, J; Gorczyca, W; Melamed, MR; Mittelman, A | 1 |
Pantazis, P | 1 |
Baguley, BC; Finlay, GJ | 1 |
Baker, SD; Evans, WE; Furman, WL; Pratt, CB; Rivera, GK; Stewart, CF | 1 |
Bertrand, R; Dubrez, L; Eymin, B; Pommier, Y; Solary, E | 1 |
Darzynkiewicz, Z; Feldman, E; Halicka, HD; Seiter, K; Traganos, F | 1 |
Buckwalter, CA; Burke, PJ; Donehower, RC; Gore, SD; Grochow, LB; Jones, RJ; Kaufmann, SH; Kottke, T; Letendre, L; Rowinsky, EK; Svingen, PA | 1 |
Bryant, M; Eder, JP; Grossbard, M; Huberman, M; Hurwitz, S; Kinchla, N; Kufe, DW; Lynch, T; Rodriguez, D; Rubin, E; Schnipper, L; Shapiro, C; Shulman, L; Stone, R; Supko, J; Toppmeyer, D; Vosburg, E; Xu, G | 1 |
Charron, M; Kaufmann, SH; Peereboom, D | 1 |
Mashima, T; Tsuruo, T | 1 |
Allouche, M; Dubrez, L; Eymin, B; Solary, E | 1 |
Armstrong, DK; Cheng, YC; Gore, SD; Kaufmann, SH; Rowinsky, EK; Svingen, PA | 1 |
Gupta, E; Ibrahim, N; Li, XG; Mendoza, J; Pantazis, P; Patel, M; Rubin, EH; Saleem, A | 1 |
Eckhardt, SG | 1 |
Rosen, LS | 1 |
Chanock, SJ; Hiraoka, W; Nieves-Neira, W; Pommier, Y; Vazquez, N | 1 |
Chatterjee, D; Han, Z; Pantazis, P; Wyche, J | 1 |
Bascans, E; Belaud-Rotureau, MA; Belloc, F; Braz-Pereira, E; Durrieu, F; Lacombe, F; Lavignolle, V | 1 |
Bradbury, DA; Crouch, SP; Simmons, TD; Slater, KJ | 1 |
Adams, DJ; Bass, AJ; Davis, P; DeCastro, CM; Foster, T; Gockerman, JP; Hammett, E; Moore, JO; Payne, N; Rizzieri, DA; Rosner, GL | 1 |
Donehower, RC; Grochow, LB; Hendricks, CB; Kaufmann, SH; Rowinsky, EK | 1 |
D'Incalci, M; Erba, E; Gervasoni, M; Lampasona, V; McSheehy, PM | 1 |
Cotter, TG; Glynn, JM; Green, DR; Lennon, SV | 1 |
Arima, T; Ariyoshi, H; Ichimaru, M; Kuramoto, A; Masaoka, T; Oguro, M; Ohno, R; Okada, K; Sakai, Y; Yoshida, Y | 1 |
Chou, S; Kaneko, M; Nakamura, Y; Nakaya, K | 1 |
6 review(s) available for camptothecin and Leukemia
Article | Year |
---|---|
Homocamptothecins: potent topoisomerase I inhibitors and promising anticancer drugs.
Topics: Animals; Antineoplastic Agents; Camptothecin; DNA Topoisomerases, Type I; Drug Design; Drug Resistance, Neoplasm; Enzyme Inhibitors; Humans; Leukemia; Topoisomerase I Inhibitors | 2003 |
[Clinical trials of new antitumor drugs in hematopoietic malignancies].
Topics: Acute Disease; Antineoplastic Agents, Phytogenic; Camptothecin; Clinical Trials as Topic; Doxorubicin; Ethics, Medical; Humans; Idarubicin; Irinotecan; Leukemia; Lymphoma | 1994 |
The water-insoluble camptothecin analogues: promising drugs for the effective treatment of haematological malignancies.
Topics: Animals; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Biotransformation; Camptothecin; Cell Differentiation; DNA Topoisomerases, Type I; Drug Resistance, Neoplasm; Humans; Leukemia; Leukemia, Experimental; Lymphoma; Mice; Phosphorylation; Solubility; Topoisomerase I Inhibitors; Tumor Cells, Cultured | 1995 |
Factors affecting topotecan sensitivity in human leukemia samples.
Topics: Antineoplastic Agents; Camptothecin; Cell Differentiation; Clinical Trials, Phase I as Topic; Drug Resistance; Drug Screening Assays, Antitumor; Enzyme Inhibitors; Forecasting; Humans; Leukemia; Topoisomerase I Inhibitors; Topotecan; Tumor Cells, Cultured | 1996 |
Topoisomerases in human leukemia.
Topics: Antineoplastic Agents; Camptothecin; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; Drug Resistance, Neoplasm; Hematopoietic System; Humans; Leukemia; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors | 1994 |
Irinotecan in lymphoma, leukemia, and breast, pancreatic, ovarian, and small-cell lung cancers.
Topics: Animals; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Camptothecin; Carcinoma, Non-Small-Cell Lung; Female; Humans; Irinotecan; Leukemia; Lung Neoplasms; Lymphoma; Neoplasms; Ovarian Neoplasms; Pancreatic Neoplasms | 1998 |
6 trial(s) available for camptothecin and Leukemia
Article | Year |
---|---|
Camptothecin analogues: studies from the Johns Hopkins Oncology Center.
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Drug Administration Schedule; Granulocyte Colony-Stimulating Factor; Humans; Infusions, Intravenous; Irinotecan; Kidney; Leukemia; Liver; Metabolic Clearance Rate; Neoplasms; Platelet Count; Topoisomerase I Inhibitors; Topotecan | 1994 |
Phase I and pharmacodynamic study of the topoisomerase I-inhibitor topotecan in patients with refractory acute leukemia.
Topics: Acute Disease; Adult; Aged; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Blotting, Western; Camptothecin; Daunorubicin; Drug Administration Schedule; Drug Resistance, Multiple; Female; Follow-Up Studies; Humans; Immunohistochemistry; Leukemia; Male; Middle Aged; Mouth Mucosa; Quinidine; Remission Induction; Stomatitis; Topoisomerase I Inhibitors; Topotecan; Tumor Cells, Cultured; Tumor Stem Cell Assay | 1994 |
Phase I study of Topotecan, a new topoisomerase I inhibitor, in patients with refractory or relapsed acute leukemia.
Topics: Acute Disease; Adult; Aged; Antineoplastic Agents; Camptothecin; DNA; DNA Topoisomerases, Type I; Drug Administration Schedule; Female; Humans; Irinotecan; Leukemia; Male; Middle Aged; Topoisomerase I Inhibitors; Topotecan | 1993 |
Escalating systemic exposure of continuous infusion topotecan in children with recurrent acute leukemia.
Topics: Acute Disease; Adolescent; Adult; Antineoplastic Agents; Camptothecin; Child; Child, Preschool; Dose-Response Relationship, Drug; Female; Half-Life; Humans; Infant; Infusions, Intravenous; Leukemia; Male; Metabolic Clearance Rate; Recurrence; Topotecan | 1996 |
Trials of 9-amino-20(S)-camptothecin in Boston.
Topics: Adult; Antineoplastic Agents; Boston; Breast Neoplasms; Camptothecin; DNA Topoisomerases, Type I; Female; Humans; Leukemia; Male; Middle Aged; Neoplasms | 1996 |
Phase I evaluation of prolonged-infusion gemcitabine with irinotecan for relapsed or refractory leukemia or lymphoma.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Camptothecin; Deoxycytidine; Drug Administration Schedule; Esophagitis; Evaluation Studies as Topic; Female; Gemcitabine; Humans; Infusions, Intravenous; Irinotecan; Leukemia; Lymphoma; Male; Middle Aged; Nausea; Neutropenia; Recurrence; Stomatitis; Treatment Outcome; Vomiting | 2002 |
46 other study(ies) available for camptothecin and Leukemia
Article | Year |
---|---|
Nuphar alkaloids with immediately apoptosis-inducing activity from Nuphar pumilum and their structural requirements for the activity.
Topics: Alkaloids; Animals; Antineoplastic Agents; Apoptosis; Cells, Cultured; Fibroblasts; Humans; In Situ Nick-End Labeling; Leukemia; Melanoma, Experimental; Mice; Nuphar; Rhizome; Sesquiterpenes; Structure-Activity Relationship | 2006 |
Synthesis and antitumoral activity of novel thiazolobenzotriazole, thiazoloindolo[3,2-c]quinoline and quinolinoquinoline derivatives.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; DNA; DNA Topoisomerases, Type I; Female; Humans; Indoles; Leukemia; Quinolines; Thiazoles; Topoisomerase I Inhibitors; Triazoles | 2009 |
Structure-activity relationship and molecular mechanisms of ethyl 2-amino-4-(2-ethoxy-2-oxoethyl)-6-phenyl-4h-chromene-3-carboxylate (sha 14-1) and its analogues.
Topics: Apoptosis; Benzopyrans; Camptothecin; Cell Line, Tumor; Drug Resistance, Neoplasm; Humans; Leukemia; Mitoxantrone; Structure-Activity Relationship | 2009 |
Discovery of antitumor anthra[2,3-b]furan-3-carboxamides: Optimization of synthesis and evaluation of antitumor properties.
Topics: Animals; Anthracenes; Antineoplastic Agents; Cell Line, Tumor; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Furans; Humans; Leukemia; Mice; Neoplasms; Protein Kinase Inhibitors; Structure-Activity Relationship; Topoisomerase Inhibitors | 2016 |
Induction of apoptosis and differentiation by atractylenolide-1 isolated from Atractylodes macrocephala in human leukemia cells.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Atractylodes; Cell Differentiation; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Humans; Lactones; Leukemia; Molecular Structure; Sesquiterpenes; Structure-Activity Relationship | 2016 |
PU.1, a novel caspase-3 substrate, partially contributes to chemotherapeutic agents-induced apoptosis in leukemic cells.
Topics: Antineoplastic Agents; Apoptosis; Aspartic Acid; Camptothecin; Caspase 3; Caspase Inhibitors; Cell Line, Tumor; Cysteine Proteinase Inhibitors; Etoposide; Humans; Leukemia; Mutagenesis, Site-Directed; Oligopeptides; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; RNA, Small Interfering; Trans-Activators | 2009 |
Nuclear translocation of dihydrofolate reductase is not a pre-requisite for DNA damage induced apoptosis.
Topics: Amino Acid Sequence; Apoptosis; Camptothecin; Caspase 3; Cell Line, Tumor; Cell Nucleus; DNA Damage; Dose-Response Relationship, Drug; Endoplasmic Reticulum; Enzyme Activation; Etoposide; Humans; Leukemia; Methotrexate; Microtubules; Molecular Sequence Data; Neoplasm Proteins; Protein Transport; Tetrahydrofolate Dehydrogenase | 2009 |
Evodiamine, a dual catalytic inhibitor of type I and II topoisomerases, exhibits enhanced inhibition against camptothecin resistant cells.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Cell Line, Tumor; Cell Proliferation; DNA Damage; DNA Topoisomerases; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; Drug Resistance, Neoplasm; Drugs, Chinese Herbal; Evodia; Fruit; Humans; Inhibitory Concentration 50; Leukemia; Phytotherapy; Quinazolines; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors; Topoisomerase Inhibitors | 2012 |
A note on Evodia rutaecarpa.
Topics: Camptothecin; DNA Topoisomerases; Drug Resistance, Neoplasm; Humans; Leukemia; Phytotherapy; Quinazolines; Topoisomerase Inhibitors | 2012 |
Reversal of multidrug resistance-associated protein-mediated daunorubicin resistance by camptothecin.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Camptothecin; Cell Line; Cell Nucleus; Chemokines, CC; Daunorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Flow Cytometry; Fluorescent Antibody Technique; Gene Expression Regulation, Neoplastic; Humans; Leukemia; Microscopy, Confocal; Reverse Transcriptase Polymerase Chain Reaction; Tetrazolium Salts; Thiazoles; Tumor Cells, Cultured | 2002 |
Exposure of cells to static magnetic field accelerates loss of integrity of plasma membrane during apoptosis.
Topics: Apoptosis; Camptothecin; Cell Count; Cell Membrane; Cell Survival; Flow Cytometry; HL-60 Cells; Humans; Image Cytometry; Leukemia; Magnetics; Necrosis | 2002 |
CPT-11-induced cell death in leukemic cells is not affected by the MDR phenotype.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily B, Member 1; Blood Cells; Bone Marrow Cells; Camptothecin; Cell Death; Drug Resistance, Multiple; Female; Humans; Interphase; Irinotecan; Leukemia; Leukocytes, Mononuclear; Male; Middle Aged; Multidrug Resistance-Associated Proteins; Phenotype; Rhodamine 123; Topoisomerase I Inhibitors; Tumor Cells, Cultured | 2003 |
Early changes in metabolism of leukemic cell lines upon induction of apoptosis by cytotoxic drugs.
Topics: Amiloride; Antineoplastic Agents, Phytogenic; Apoptosis; Camptothecin; DNA Fragmentation; Dose-Response Relationship, Drug; Humans; Hydrogen-Ion Concentration; K562 Cells; Leukemia; Paclitaxel; Sodium Azide; U937 Cells | 2003 |
Endoplasmic reticulum chaperone protein GRP78 protects cells from apoptosis induced by topoisomerase inhibitors: role of ATP binding site in suppression of caspase-7 activation.
Topics: Adenosine Triphosphate; Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Apoptosis; Binding Sites; Camptothecin; Carrier Proteins; Caspase 7; Caspases; Cell Membrane; Cricetinae; Doxorubicin; Endoplasmic Reticulum; Endoplasmic Reticulum Chaperone BiP; Enzyme Precursors; Etoposide; G1 Phase; Gene Expression; Heat-Shock Proteins; Humans; Leukemia; Molecular Chaperones; Protein Structure, Tertiary; Subcellular Fractions; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors; Transfection; Tumor Cells, Cultured; Urinary Bladder Neoplasms | 2003 |
Camptothecin- and etoposide-induced apoptosis in human leukemia cells is independent of cell death receptor-3 and -4 aggregation but accelerates tumor necrosis factor-related apoptosis-inducing ligand-mediated cell death.
Topics: Adaptor Proteins, Signal Transducing; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Apoptosis Regulatory Proteins; Camptothecin; CASP8 and FADD-Like Apoptosis Regulating Protein; Etoposide; Fas-Associated Death Domain Protein; Gene Deletion; Genes, Dominant; HL-60 Cells; Humans; Intracellular Signaling Peptides and Proteins; Leukemia; Ligands; Membrane Glycoproteins; Receptors, TNF-Related Apoptosis-Inducing Ligand; Receptors, Tumor Necrosis Factor; Receptors, Tumor Necrosis Factor, Member 25; TNF-Related Apoptosis-Inducing Ligand; Transfection; Tumor Necrosis Factor Ligand Superfamily Member 15; Tumor Necrosis Factor Receptor-Associated Peptides and Proteins; Tumor Necrosis Factor-alpha; TWEAK Receptor; U937 Cells | 2004 |
Nanomolar concentration of NSC606985, a camptothecin analog, induces leukemic-cell apoptosis through protein kinase Cdelta-dependent mechanisms.
Topics: Antineoplastic Agents; Apoptosis; Camptothecin; Caspase 3; Caspases; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Enzyme Activation; Humans; Intracellular Membranes; Leukemia; Membrane Potentials; Mitochondria; Protein Kinase C; Protein Kinase C-delta | 2005 |
Analysis of resonance chemotherapy in leukemia treatment via multi-staged population balance models.
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Cell Cycle; Cell Death; Cell Division; Coculture Techniques; Drug Administration Schedule; Half-Life; HL-60 Cells; Humans; Jurkat Cells; Leukemia; Models, Biological | 2006 |
Cytotoxic effects of histone deacetylase inhibitor FK228 (depsipeptide, formally named FR901228) in combination with conventional anti-leukemia/lymphoma agents against human leukemia/lymphoma cell lines.
Topics: Antineoplastic Agents; Apoptosis; Benzamides; Camptothecin; Carboplatin; Cell Line, Tumor; Cell Survival; Cyclophosphamide; Cytarabine; Depsipeptides; Dose-Response Relationship, Drug; Doxorubicin; Drug Synergism; Etoposide; Histone Deacetylase Inhibitors; HL-60 Cells; Humans; Imatinib Mesylate; Irinotecan; K562 Cells; Leukemia; Lymphoma; Mercaptopurine; Piperazines; Pyrimidines; Time Factors | 2007 |
Involvement of caspase-8 in chemotherapy-induced apoptosis of patient derived leukemia cell lines independent of the death receptor pathway and downstream from mitochondria.
Topics: Antineoplastic Agents; Apoptosis; Camptothecin; Caspase 8; Caspase 9; Cell Line, Tumor; Daunorubicin; Enzyme Activation; Humans; Leukemia; Mitochondria; Receptors, Death Domain | 2007 |
A renewed call for equipoise.
Topics: Adenocarcinoma; Camptothecin; Chemotherapy, Adjuvant; Colonic Neoplasms; Disease-Free Survival; Ethics, Medical; Fluorouracil; Humans; Irinotecan; Leucovorin; Leukemia; Randomized Controlled Trials as Topic; Recurrence; Treatment Outcome; Uncertainty | 2007 |
Synergy of karenitecin and mafosfamide in pediatric leukemia, medulloblastoma, and neuroblastoma cell lines.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cell Line, Tumor; Child; Cyclophosphamide; Drug Synergism; Humans; Leukemia; Medulloblastoma; Neuroblastoma | 2008 |
Anti proliferative activity of ELACY (CP-4055) in combination with cloretazine (VNP40101M), idarubicin, gemcitabine, irinotecan and topotecan in human leukemia and lymphoma cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cell Line, Tumor; Cytarabine; Deoxycytidine; Drug Interactions; Drug Screening Assays, Antitumor; Gemcitabine; Humans; Hydrazines; Idarubicin; Irinotecan; Leukemia; Lymphoma; Sulfonamides; Topotecan | 2008 |
The role of cell cycle regulation and apoptosis triggering in determining the sensitivity of leukemic cells to topoisomerase I and II inhibitors.
Topics: Apoptosis; Base Sequence; Camptothecin; Cell Cycle; Cell Line; Cell Survival; DNA Damage; DNA Primers; DNA, Neoplasm; Dose-Response Relationship, Drug; Etoposide; Humans; Leukemia; Microscopy, Electron; Molecular Sequence Data; Polymerase Chain Reaction; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors; Tumor Cells, Cultured | 1995 |
Sensitivity of camptothecin-resistant human leukemia cells and tumors to anticancer drugs with diverse mechanisms of action.
Topics: Animals; Antineoplastic Agents; Apoptosis; Camptothecin; Cell Cycle; Cell Division; DNA, Neoplasm; Drug Resistance; Drug Screening Assays, Antitumor; Flow Cytometry; Humans; Leukemia; Male; Mice; Mice, Nude; Topoisomerase II Inhibitors | 1995 |
Mutation at the catalytic site of topoisomerase I in CEM/C2, a human leukemia cell line resistant to camptothecin.
Topics: Amino Acid Sequence; Animals; Base Sequence; Camptothecin; Cricetinae; Cricetulus; DNA Topoisomerases, Type I; Drug Resistance; Humans; Leukemia; Molecular Sequence Data; Point Mutation; Recombinant Proteins; Tumor Cells, Cultured | 1995 |
Partial characterization of human leukemia U-937 cell sublines resistant to 9-nitrocamptothecin.
Topics: Animals; Antineoplastic Agents; Camptothecin; Cell Adhesion; Cell Differentiation; Cell Division; DNA Topoisomerases, Type I; DNA, Neoplasm; Drug Resistance; Flow Cytometry; Humans; Leukemia; Male; Mice; Mice, Nude; Monocytes; Tetradecanoylphorbol Acetate; Tumor Cells, Cultured | 1994 |
Quantification of topoisomerase-DNA complexes in leukemia cells from patients undergoing therapy with a topoisomerase-directed agent.
Topics: Amsacrine; Antineoplastic Agents; Camptothecin; DNA Probes; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; DNA, Neoplasm; Drug Resistance; Etoposide; Humans; Immunoblotting; Leukemia; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors; Topotecan; Tumor Cells, Cultured | 1994 |
A selective procedure for DNA extraction from apoptotic cells applicable for gel electrophoresis and flow cytometry.
Topics: Apoptosis; Bone Marrow; Camptothecin; DNA, Neoplasm; Electrophoresis; Ethanol; Flow Cytometry; Humans; Leukemia; Leukemia, Promyelocytic, Acute; Time Factors; Tumor Cells, Cultured | 1994 |
Induction of DNA strand breaks associated with apoptosis during treatment of leukemias.
Topics: Adult; Aged; Alkenes; Antineoplastic Agents; Apoptosis; Camptothecin; DNA Damage; DNA Nucleotidylexotransferase; DNA, Neoplasm; Gamma Rays; Humans; In Vitro Techniques; Leukemia; Male; Middle Aged; Polyenes; Pyrones; Tumor Cells, Cultured | 1993 |
Pharmacokinetic/cytokinetic principles in the chemotherapy of solid tumours.
Topics: Acridines; Antineoplastic Agents; Camptothecin; Cell Cycle; Drug Design; Drug Screening Assays, Antitumor; Humans; Leukemia; Paclitaxel; Tumor Cells, Cultured | 1995 |
[Apoptosis of human leukemic cells induced by topoisomerase I and II inhibitors].
Topics: Alkaloids; Apoptosis; Camptothecin; Cell Cycle; Cell Differentiation; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; DNA, Neoplasm; Etoposide; Humans; Leukemia; Protein Kinase C; Signal Transduction; Staurosporine; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors; Tumor Cells, Cultured | 1996 |
Induction of apoptosis by camptothecin and topotecan.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Bone Marrow; Camptothecin; Cell Cycle; Cytarabine; DNA Damage; Enzyme Inhibitors; HL-60 Cells; Humans; Leukemia; Topotecan | 1996 |
[Involvement of ICE/CED 3 family proteases in antitumor agent-induced apoptosis].
Topics: Antineoplastic Agents; Apoptosis; Camptothecin; Caspase 1; Cycloheximide; Cysteine Endopeptidases; Cytarabine; Doxorubicin; Humans; Leukemia; Tumor Cells, Cultured; Tumor Necrosis Factor-alpha | 1997 |
Increased gadd153 messenger RNA level is associated with apoptosis in human leukemic cells treated with etoposide.
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Apoptosis; Camptothecin; CCAAT-Enhancer-Binding Proteins; Daunorubicin; DNA Fragmentation; DNA-Binding Proteins; Etoposide; HL-60 Cells; Humans; Leukemia; Nuclear Proteins; RNA, Messenger; Serine Proteinase Inhibitors; Transcription Factor CHOP; Transcription Factors; Tumor Cells, Cultured | 1997 |
Altered formation of topotecan-stabilized topoisomerase I-DNA adducts in human leukemia cells.
Topics: Antineoplastic Agents; Camptothecin; DNA Adducts; DNA Topoisomerases, Type I; DNA, Neoplasm; Drug Resistance, Neoplasm; Electrophoresis, Polyacrylamide Gel; Enzyme Stability; Humans; Leukemia; Prospective Studies; Topotecan | 1997 |
Mechanisms of resistance in a human cell line exposed to sequential topoisomerase poisoning.
Topics: Antineoplastic Agents; Camptothecin; Cell Nucleus; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; Drug Resistance, Neoplasm; Etoposide; Humans; Leukemia; Phenotype; Point Mutation; RNA, Messenger; Tumor Cells, Cultured | 1997 |
Irinotecan: a review of the initial phase I trials.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Dose-Response Relationship, Drug; Drug Administration Schedule; France; Hodgkin Disease; Humans; Irinotecan; Japan; Leukemia; Lymphoma, Non-Hodgkin; United States | 1998 |
Role of oxygen radicals generated by NADPH oxidase in apoptosis induced in human leukemia cells.
Topics: Alkaloids; Antineoplastic Agents, Phytogenic; Antioxidants; Apoptosis; Camptothecin; Catalase; Cell Differentiation; Cell Line; DNA Fragmentation; Enzyme Inhibitors; Etoposide; Flow Cytometry; Granulomatous Disease, Chronic; Humans; Hydrogen Peroxide; Leukemia; Membrane Glycoproteins; Monocytes; NADPH Oxidase 2; NADPH Oxidases; Neoplasm Proteins; Neutrophils; NF-kappa B; Pyrrolidines; Reactive Oxygen Species; Staurosporine; Thiocarbamates; Topoisomerase I Inhibitors; Tumor Cells, Cultured; Ultraviolet Rays | 1998 |
Modulation of 9-nitrocamptothecin-induced apoptosis by hyperthermia in human leukemia HL-60 cells.
Topics: Antineoplastic Agents; Apoptosis; Camptothecin; Flow Cytometry; HL-60 Cells; Humans; Hyperthermia, Induced; Leukemia | 1999 |
Flow cytometry detection of caspase 3 activation in preapoptotic leukemic cells.
Topics: Adult; Annexin A5; Antibiotics, Antineoplastic; Antibodies, Monoclonal; Apoptosis; Biomarkers; Blotting, Western; Bone Marrow Cells; Camptothecin; Caspase 3; Caspase 7; Caspases; Daunorubicin; Enzyme Activation; Enzyme Inhibitors; Flow Cytometry; Fluorescein-5-isothiocyanate; Fluorescent Dyes; Humans; Idarubicin; Leukemia; Peptide Hydrolases; Protein Binding; U937 Cells | 2000 |
Measurement of the ADP:ATP ratio in human leukaemic cell lines can be used as an indicator of cell viability, necrosis and apoptosis.
Topics: Adenosine Diphosphate; Adenosine Triphosphate; Apoptosis; Camptothecin; Cell Death; Cell Survival; Dexamethasone; Energy Metabolism; HL-60 Cells; Humans; In Situ Nick-End Labeling; Jurkat Cells; Leukemia; Microscopy, Fluorescence; Necrosis; U937 Cells | 2000 |
Effect of P-glycoprotein expression on the accumulation and cytotoxicity of topotecan (SK&F 104864), a new camptothecin analogue.
Topics: Acute Disease; Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Breast Neoplasms; Camptothecin; CHO Cells; Cricetinae; DNA Topoisomerases, Type I; DNA, Neoplasm; Doxorubicin; Drug Resistance; Drug Screening Assays, Antitumor; Flow Cytometry; Leukemia; Membrane Glycoproteins; Quinidine; Topotecan; Tumor Cells, Cultured | 1992 |
Studies of the differentiation properties of camptothecin in the human leukaemic cells K562.
Topics: Camptothecin; Cell Differentiation; Dose-Response Relationship, Drug; Down-Regulation; Globins; Humans; Leukemia; Lymphocytes, Null; Methotrexate; Mitosis; RNA, Messenger; Topoisomerase I Inhibitors; Tumor Cells, Cultured | 1991 |
Microfilament-disrupting agents prevent the formation of apoptotic bodies in tumor cells undergoing apoptosis.
Topics: Actin Cytoskeleton; Aphidicolin; Camptothecin; Cell Death; Cell Line; Cell Survival; Cytochalasin B; Humans; Ionomycin; Kinetics; Leukemia; Tetradecanoylphorbol Acetate; Ultraviolet Rays | 1992 |
An early phase II study of CPT-11: a new derivative of camptothecin, for the treatment of leukemia and lymphoma.
Topics: Adolescent; Adult; Antineoplastic Agents, Phytogenic; Camptothecin; Drug Evaluation; Female; Humans; Irinotecan; Leukemia; Lymphoma; Male; Middle Aged | 1990 |
Induction of differentiation of human and mouse myeloid leukemia cells by camptothecin.
Topics: Animals; Biomarkers; Camptothecin; Cell Differentiation; Cell Line; Humans; Kinetics; Leukemia; Leukemia, Experimental; Mice; Phagocytosis; Receptors, Fc; Time Factors; Tumor Cells, Cultured | 1990 |